Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 1/2 3Phase 1 3Phase 2/3 2Phase 3 1

Status

Unknown 2Active not recruiting 2Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Stomach Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 13Paclitaxel 11Cyclophosphamide 11Doxorubicin 10Magnetic Resonance Spectroscopy 9Gemcitabine 9Prednisone 8Docetaxel 8Specimen Handling 7Oxaliplatin 7Carboplatin 7Vincristine 6Etoposide 6Capecitabine 6pembrolizumab 5Rituximab 5Radiotherapy 5Leucovorin 5Cytarabine 5Bevacizumab 5atezolizumab 4Trastuzumab 4Platinum 4Nivolumab 4Fluorouracil 4Dexamethasone 4Biopsy 41,2-diaminocyclohexaneplatinum II citrate 4Watchful Waiting 3Taxes 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Active not recruiting × toripalimab × Clear all
NCT06984588 2026-01-30

A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer

TJ Biopharma Co., Ltd.

Phase 2/3 Active not recruiting
450 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05980481 2025-09-29

A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer

RemeGen Co., Ltd.

Phase 2/3 Active not recruiting
201 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡